In December 2019, an outbreak of novel Coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to similar to 2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.
基金：
Tongji Hospital Clinical Research Flagship Program [2019CR207]
第一作者单位：[1]huazhong univ sci & technol,tongji hosp,tongji med coll,div cardiol,wuhan 430030,peoples r china
通讯作者：
推荐引用方式(GB/T 7714)：
Ni Li,Zhou Ling,Zhou Min,et al.Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan[J].FRONTIERS OF MEDICINE.2020,14(2):210-214.doi:10.1007/s11684-020-0757-x.
APA：
Ni,Li,Zhou,Ling,Zhou,Min,Zhao,Jianping&Wang, Dao Wen.(2020).Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan.FRONTIERS OF MEDICINE,14,(2)
MLA：
Ni,Li,et al."Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan".FRONTIERS OF MEDICINE 14..2(2020):210-214
